Insider transaction
Brian J. Caveney, who serves as Executive Vice President at Labcorp Holdings Inc (NYSE: LH), sold 1,500 shares of the company's common stock on February 24, 2026 at a per-share price of $286.305. The sale produced total proceeds of $429,457.
The disposition occurred while Labcorp's shares were trading near the 52-week high of $293.72, and against a backdrop of analyst price targets that span from $260 to $342.
After completing the sale, Caveney's direct ownership in Labcorp stands at 30,106.9234 shares.
Financial context and operational update
Labcorp released its fourth-quarter 2025 financial results showing earnings per share of $4.07, ahead of the consensus forecast of $3.93. Revenue for the quarter was $3.52 billion, which fell short of the expected $3.56 billion.
In parallel with its quarterly report, Labcorp announced an expanded collaboration with PathAI to deploy the AISight Dx digital pathology platform throughout its national network of anatomic pathology laboratories and hospital partnerships. The platform is FDA-cleared and cloud-based, enabling pathologists to digitally manage slides and apply artificial intelligence tools intended to support diagnostic workflows. The rollout is designed to enhance case management, slide review, collaboration, and annotation within Labcorp's anatomic pathology operations.
For investors seeking additional analytical resources related to Labcorp's valuation and operational performance, InvestingPro is mentioned as offering access to nine additional ProTips and comprehensive financial metrics.
Summary
- Brian J. Caveney sold 1,500 Labcorp shares on February 24, 2026 at $286.305 per share, totaling $429,457.
- The stock was trading near its 52-week high of $293.72 at the time of the sale, with analyst targets ranging from $260 to $342.
- Post-transaction direct holdings for Caveney are 30,106.9234 shares.
- Labcorp's Q4 2025 EPS of $4.07 exceeded the $3.93 estimate, while revenue of $3.52 billion missed the $3.56 billion forecast.
- Labcorp expanded deployment of the FDA-cleared AISight Dx digital pathology platform with PathAI across its anatomic pathology network to improve case management and diagnostics.
Key points
- Insider sale: A senior executive sold 1,500 shares, generating $429,457, reducing his direct holdings to 30,106.9234 shares - relevant to investors monitoring insider activity.
- Valuation context: The transaction occurred near a 52-week high with analysts' price targets spanning $260 to $342 - providing a range of market expectations.
- Operational developments: Labcorp beat EPS estimates for Q4 2025 but missed on revenue, and is advancing digital pathology capabilities through an expanded PathAI collaboration.
Risks and uncertainties
- Revenue shortfall risk - Labcorp's Q4 2025 revenue missed expectations, which could influence near-term investor sentiment in the healthcare diagnostics sector.
- Execution risk for technology rollout - The expanded AISight Dx deployment aims to improve pathology workflows, but the article does not provide details on timing or measurable outcomes.
- Analyst target dispersion - Analyst price targets range from $260 to $342, indicating differing expectations among market analysts about Labcorp's valuation.
These developments touch the healthcare diagnostics and medical technology sectors, as well as capital markets where insider trades and earnings outcomes are monitored by investors.